Publications

2024

Jacques Neefjes, Katerina Gurova, Jay Sarthy, Gábor Szabó , Steven Henikoff

Chromatin as an old and new anticancer target. Trends in Cancer, 2024 June 1.

Carla A Jaeger-Ruckstuhl, Yun Lo, Elena Fulton, Olivia G Waltner, Tamer B Shabaneh, Sylvain Simon, Pranav V Muthuraman, Colin E Correnti, Oliver J Newsom, Ian A Engstrom, Sami B Kanaan, Shruti S Bhise, Jobelle M C Peralta, Raymond Ruff, Jason P Price, Sylvia M Stull, Andrew R Stevens, Grace Bugos, Mitchell G Kluesner, Valentin Voillet, Vishaka Muhunthan, Fionnuala Morrish, James M Olson, Raphaël Gottardo, Jay F Sarthy, Steven Henikoff, Lucas B Sullivan, Scott N Furlan, Stanley R Riddell

Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 2024 Feb 13.

2023

Derek H Janssens, Melodie Duran, Dominik J Otto, Danielle Kirkey, Joanna S Yi, Soheil Meshinchi, Jay F Sarthy, Kami Ahmad, Steven Henikoff

KMT2A oncoproteins induce epigenetic resistance to targeted therapies. bioRxiv, 2023 Dec 30.

Abby Trouth, Kamesh Ravichandran, Phillip R Gafken, Sara Martire, Stephanie J. Namciu, Laura A. Banaszynski, Jay F. Sarthy, Srinivas Ramachandran

G1 length dictates heterochromatin landscape. bioRxiv, 2023 Dec 7.

Samantha Kaonis, Jenny L Smith, Neerja Katiyar, Morgan Merrill, Tiffany Hylkema, Stephanie Namciu, Quy Le, Ekaterina Babaeva, Takashi Ikeda, Shelli M Morris, Emily Girard, Suzanne Furuyama, Rhonda Ries, Irwin Bernstein, Soheil Meshinchi, Steven Henikoff, Michael P. Meers, Brandon K Hadland, Jay F. Sarthy

Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. bioRxiv, 2023 Sep 1.

De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G

Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate
Cancer Phenotypes. Cancer Discovery, 2023 Mar 1

2022

Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Brodersen L, Riddell SR, Tarlock K,
Bernstein ID, Loeb KR, Meshinchi S

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

The Journal of Clinical Investigation, 2022 Nov 15

Apfelbaum AA, Wu F, Hawkins AG, Magnuson B, Jiménez JA, Taylor SD, Wrenn ED, Waltner O, Pfaltzgraff ER, Song JY, Hall C, Wellik DM, Ljungman M, Furlan SN, Ryan RJH, Sarthy JF, Lawlor ER

EWS-FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma. Clinical Cancer Research, 2022 Oct 14

Levy S, Somasundaram L, Raj IX, Ic-Mex D, Phal A, Schmidt S, Ng WI, Mar D, Decarreau J, Moss N, Alghadeer A, Honkanen H, Sarthy J, Vitanza A, Hawkins RD, Mathieu J, Wang Y, Baker D, Bomsztyk K, Ruohola-Baker H. dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter
region. Cell Reports, 2022 Mar 1

Apfelbaum AA, Wu F, Magnuson B, Hawkins AG, Jiménez JA, Taylor SD, Pfaltzgraff ER, Song JY, Hall C, Wellik DM, Ljungman M, Furlan S, Ryan RJH, Sarthy JF, Lawlor ER

HOXD13 is a direct EWS-FLI1 target and moderates fusion-dependent transcriptional states. bioRxiv, 2022 Jan 31

2021

Janssens DH, Meers MP, Wu SJ, Babaeva E, Meshinchi S, Sarthy JF, Ahmad K, Henikoff S.

Automated CUT&Tag profiling of chromatin heterogeneity in mixed- lineage leukemia. Nature Genetics, 2021 Nov

Wu SJ, Furlan SN, Mihalas AB, Kaya-Okur HS, Feroze AH, Emerson SN, Zheng Y, Carson K, Cimino PJ, Keene CD, Sarthy JF, Gottardo R, Ahmad K, Henikoff S, Patel AP.

Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progression. Nature Biotechnology, 2021 Jul

Vitanza NA, Biery MC, Myers C, Ferguson E, Zheng Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Morris SM, Sarthy J, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JM.

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. Neuro-oncology, 2021 Mar 25

Janssens DH, Wu SJ, Sarthy JF, Meers MP, Myers CH, Olson JM, Ahmad K, Henikoff S.

Automated in situ profiling of chromatin modifications resolves cell types and gene regulatory programs. bioRxiv, 2021 Mar 10

Vitanza NA, Khalatbari H, Ermoian R, Sarthy J, Lockwood CM, Cole BL, Leary SES.

Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma. The Journal of Applied Laboratory Medicine, 2021 Mar 1

Chew GL, Bleakley M, Bradley RK, Malik HS, Henikoff S, Molaro A, Sarthy J.

Short H2A histone variants are expressed in cancer. Nature communications, 2021 Jan 20

2020

Sarthy JF, Meers MP, Janssens DH, Henikoff JG, Feldman H, Paddison PJ, Lockwood CM, Vitanza NA, Olson JM, Ahmad K, Henikoff S.

Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones. eLife, 2020 Sep 9

Woerner A, Shin DS, Chick JFB, Smith CA, Sarthy JF, Monroe EJ.

Endolymphatic exclusion for the treatment of pediatric chylous ascites secondary to neuroblastoma resection: report of two cases. Radiology Case Reports, 2020 May 19

Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kamiński MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MA.

MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020 Feb 14